...
首页> 外文期刊>Eye >The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension.
【24h】

The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension.

机译:前列腺素类似物对原发性开角型青光眼和高眼压的有晶状体眼患者的血水屏障和角膜厚度的影响。

获取原文
获取原文并翻译 | 示例

摘要

Purpose:To evaluate the effects of topical latanoprost, travoprost, and bimatoprost on the blood-aqueous barrier and central corneal thickness (CCT) of patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT).Design:Prospective, randomized, masked-observer, crossover clinical trial.Methods:A total of 34 phakic patients with POAG or OHT with no previous history of intraocular surgery or uveitis completed the study. Patients were randomized to use latanoprost 0.005%, travoprost 0.004%, or bimatoprost 0.03% once daily (2000 hours) for 1 month, followed by a washout period of 4 weeks between each drug. Aqueous flare was measured with a laser flare metre. CCT was calculated as the average of five measurements using ultrasound pachymetry. All measurements were performed by a masked observer (1000 h).Results:There were no statistically significant differences between baseline mean IOP, mean CCT, and mean flare values among the groups. There was no statistically significant increase in mean flare values from baseline in all groups (P>0.05). There were no statistically significant differences between mean flare values among the groups (P>0.05). All medications significantly reduced the mean IOP from baseline (P<0.0001). IOP reduction obtained with travoprost (7.3+/-3.8 mmHg) was significantly higher than that obtained with latanoprost (4.7+/-4.2 mmHg) (P=0.01). A statistically significant reduction in mean CCT (0.6+/-1.3%) from baseline was observed when patients instilled bimatoprost (P=0.01).Conclusions:Latanoprost, travoprost, and bimatoprost had no statistically significant effect on the blood-aqueous barrier of phakic patients with POAG or OHT. Bimatoprost may be associated with a clinically irrelevant reduction in mean CCT.Eye (2008) 22, 179-183; doi:10.1038/sj.eye.6702542; published online 25 August 2006.
机译:目的:评估局部拉坦前列素,曲妥普列斯特和比马前列素对原发性开角型青光眼(POAG)和高眼压(OHT)患者的血水屏障和中央角膜厚度(CCT)的影响设计:前瞻性,随机方法:总共34例无眼内手术或葡萄膜炎病史的POAG或OHT晶状体患者完成了这项研究。患者被随机分配为每天一次(2000小时)使用拉坦前列素0.005%,特拉沃前列素0.004%或比马前列素0.03%持续1个月,然后每种药物之间的清洗期为4周。用激光耀斑米测量水耀斑。使用超声测厚仪将CCT计算为五次测量的平均值。所有测量均由一名戴着面具的观察员进行(1000 h)。结果:各组之间的基线平均IOP,平均CCT和平均耀斑值之间无统计学差异。在所有组中,平均耀斑值与基线相比均没有统计学上的显着增加(P> 0.05)。各组之间的平均耀斑值之间无统计学差异(P> 0.05)。所有药物均从基线显着降低了平均IOP(P <0.0001)。 travoprost(7.3 +/- 3.8 mmHg)所获得的IOP降低明显高于latanoprost(4.7 +/- 4.2 mmHg)(P = 0.01)。滴注比马前列素的患者的平均CCT较基线降低了统计学上的显着性(0.6 +/- 1.3%)(P = 0.01)。结论:拉坦前列素,曲伏前列素和比马前列素对有晶状体眼的血水屏障没有统计学意义POAG或OHT患者。比马前列素可能与平均CCT的临床无关降低有关.Eye(2008)22,179-183; doi:10.1038 / sj.eye.6702542;在线发布于2006年8月25日。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号